APA (7th ed.) Citation

M, S., E, M., DM, A., & T, W. (2025). [The EMBARK trial: The use of enzalutamide in biochemically recurrent prostate cancer after primary therapy]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 201(6), 666. https://doi.org/10.1007/s00066-025-02371-6

Chicago Style (17th ed.) Citation

M, Shelan, Mathier E, Aebersold DM, and Wiegel T. "[The EMBARK Trial: The Use of Enzalutamide in Biochemically Recurrent Prostate Cancer After Primary Therapy]." Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [et Al] 201, no. 6 (2025): 666. https://doi.org/10.1007/s00066-025-02371-6.

MLA (9th ed.) Citation

M, Shelan, et al. "[The EMBARK Trial: The Use of Enzalutamide in Biochemically Recurrent Prostate Cancer After Primary Therapy]." Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [et Al], vol. 201, no. 6, 2025, p. 666, https://doi.org/10.1007/s00066-025-02371-6.